BGLC vs TMO vs DHR vs A

For growth investors, Agilent Technologies, Inc.

(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). Agilent Technologies, Inc. (A) offers the better valuation at 25. 3x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Agilent Technologies, Inc.

(A) is the cheapest at 25. 3x versus Danaher Corporation at 34. 0x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 32x versus Danaher Corporation's 33. 47x — a reasonable growth-adjusted valuation.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +1. 9%, compared to -98. 6% for BioNexus Gene Lab Corp. (BGLC). Over 10 years, the gap is even starker: TMO returned +222. 6% versus BGLC's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

89β versus BioNexus Gene Lab Corp. 's 1. 56β — meaning BGLC is approximately 74% more volatile than DHR relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agilent Technologies, Inc.

(A) is pulling ahead at 6. 7% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: BioNexus Gene Lab Corp. grew EPS 41. 2% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, A leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agilent Technologies, Inc.

(A) is the more profitable company, earning 18. 8% net margin versus -16. 8% for BioNexus Gene Lab Corp. — meaning it keeps 18. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus -16. 5% for BGLC. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 32x versus Danaher Corporation's 33. 47x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 7x forward P/E versus 20. 3x for Danaher Corporation — 1. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 44. 3% to $247. 00.

In this comparison, A (0.

9% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. BGLC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

89), 0. 7% yield, +212. 4% 10Y return). BioNexus Gene Lab Corp. (BGLC) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHR: +212. 4%, BGLC: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DHR, A pay a dividend while BGLC, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.